和康生物科技股份有限公司
MAXIGEN BIOTECH INC.

2025 Q4 Investor Conference
President Cindy Chen

SAFE HARBOR NOTICE

MBI's statements of its current expectations are forward looking statements subject to significant risks and uncertainties and actual results may differ materially from those contained in the forward-looking statements. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Collagen & Hyaluronic Acid Biomedical Company

Stock Code: 1783
Employee Number: 158
Revenue (Jan–Nov 2025): NTD 719 million

1998
Company established

2006
Biomedical materials obtained U.S. FDA approval

2013
IPO

2017
Indonesia: Biomedical materials obtained marketing authorization.

2018
Russia, Malaysia and Taiwan: Biomedical materials obtained marketing authorization.

2019
EU CE certification for biomedical materials

2021
TCI Co., Ltd became the largest shareholder.

Mr. Vincent Lin elected as chairman

Obtained 3 certifications in Malaysia

2022
Obtained market authorization in Malaysia, Indonesia, Philippines, and India

Formaderm launched at the China Oriental Plastic Surgery Art Conference

2023
Approved for dental foundation
Marketed in the United Arab Emirates

Dermal filler approved for technical review in Malaysia

Expected to obtain marketing authorization in Vietnam, Australia, Egypt, Jordan, Kyrgyzstan.

2023
Total of 22 product items that have obtained certification in 2023. So far, the company has a total of 81 products with license qualifications.

2024
Joint injections approved in Saudi Arabia, Australia, and Peru; collagen dressings (HAD, HAS) approved in Vietnam and Thailand; next-generation nasal implant material (NAS) eligible to enter the U.S. and Taiwan markets.

2025
Total approved products reached 127 items.

Formaderm obtained NMPA certification.

Developing Future

2026 Direction

R & D

R&D in Regenerative Medicine

Clinical Trials 3+2

160 Certification Objectives

2026 Outlook





Entering a new medical specialty

Emerging Market Expansion

2025 Q4 Activities

Medical & Clinical Activities

- 「Naso Aid」clinical trials will soon commence at domestic medical centers; IRB applications are currently in progress at Taipei VGH, NTUH, and Linkou CGMH
- Participated in key events hosted by major domestic medical societies, including：
  Taiwan Micro-invasive Aesthetic Medicine Association、Taiwan Orthopaedic Association、
  Taiwan Academy of Periodontology、Taiwan Academy of International Implant Dentistry

Global Market Development

- Ophthalmology certification obtained in Thailand.
  2 Dental certifications obtained in Morocco.
- Commenced shipments of intra-articular injections to Egypt, with shipments to Mexico scheduled for 2026.

Expansion of Group Synergies

- Successful Sales of GLP-1 Formula in Mainland China
- Sales Growth of 633 Bone & Joint Health Supplements
- Sales Growth of Maxi Collagen

Actively Expanding the Market

Aesthetic Medicine Workshop – Belleesse Dr. Chen Chien-Ming

Health Supplement Event – Volleyball Tournament

Taiwan Orthopedic Association: Autumn Orthopedics Expo

Dental Expo – Annual Meeting of the Taiwan Academy of Periodontology

Dental Expo – Annual Meeting of the Taiwan International Dental Implant Association

Rehabilitation – Taiwan Association of Integrated Chinese and Western Medicine in Rehabilitation

Distributor Conference

Sustainability & Growth

Christmas Gifts for Sunshine Social Welfare Foundation

Brainstorming Winning Team

Q4 Birthday Party

Christmas Gifts for Sunshine Social Welfare Foundation

MBI Brainstorming

Collaboration with Yu-Cheng Social Welfare Foundation for Lunar New Year Gift Boxes

Financial Review

Sales Breakdown By Product







Q3 2025 **Q2 2025** **Q3 2024**

Sales Breakdown By Region



Q3 2025



Q2 2025



Q3 2024

Q3 2025 Income Statement

TWD'Million	2025		Q3 2025		Q2 2025		Q1 2025	
	Amount	%	Amount	%	Amount	%	Amount	%
Operating Revenue	**587**	**100%**	**201**	**100%**	**209**	**100%**	**177**	**100%**
Gross Margin	398	68%	135	67%	138	66%	125	71%
Operating Expenses	**-224**	**-38%**	**-82**	**-41%**	**-69**	**-33%**	**-73**	**-41%**
- Selling	-70	-12%	-18	-9%	-22	-11%	-30	-17%
- G&A	-72	-12%	-28	-14%	-20	-10%	-24	-13%
- R&D	-92	-16%	-33	-17%	-27	-13%	-32	-18%
- Expected Credit Losses	10	2%	-3	-1%	0	0%	13	7%
Operating Profit	**175**	**30%**	**54**	**27%**	**69**	**33%**	**52**	**29%**
Non-Operating Income	28	5%	36	18%	-16	-8%	8	4%
Income Tax	-21	-4%	-14	-7%	6	3%	-13	-7%
Net Profit After Tax	**182**	**31%**	**76**	**38%**	**59**	**28%**	**47**	**27%**
Net Profit Attributable to Shareholders of the Parent	182	31%	76	38%	59	28%	47	27%
Basic EPS	**2.02**		**0.84**		**0.65**		**0.53**	

Q3 2025 Balance Sheet

selected items from balance sheet (in TWD $ million)	Q3 2025		Q2 2025		Q1 2025		Q3 2024	
	Amount	%	Amount	%	Amount	%	Amount	%
Cash & Cash Equivalent	733	43%	739	44%	704	42%	545	36%
Account Receivables	122	7%	106	6%	87	5%	113	7%
Inventories	81	5%	74	4%	74	4%	75	5%
Net PP&E	771	45%	773	46%	831	49%	800	52%
Total Assets	**1,708**	**100%**	**1,692**	**100%**	**1,696**	**100%**	**1,533**	**100%**
Short-Term Debt	-	0%	-	0%	-	0%	-	0%
Current Liabilities	234	14%	279	16%	218	13%	198	13%
Total Liabilities	**234**	**14%**	**279**	**16%**	**218**	**13%**	**198**	**13%**
Total Shareholders' Equity	**1,474**	**86%**	**1,413**	**84%**	**1,478**	**87%**	**1,335**	**87%**

Q3 2025 Cash Flow Statement

(in TWD $ million)	Q3 2025	Q2 2025	Q1 2025	Q3 2024
	Amount	Amount	Amount	Amount
Beginning Balance	639	639	639	431
Cash from Ops.	194	111	74	215
Cash from Investing	- 38	- 26	- 16	- 20
Cash from Financing	- 68	6	7	- 80
Foreign Exchange Rate Adj.	4	8	- 2	- 2
Ending Balance	731	738	703	544

THANK YOU